Controlling Cancer Cell Death Types to Optimize Anti-Tumor Immunity

Over several decades, cell biology research has characterized distinct forms of regulated cell death, identified master regulators such as nuclear factor kappa B (NF kappa B), and contributed to translating these findings in order to improve anti-cancer therapies. In the era of immunotherapy, however, the field warrants a new appraisal-the targeted induction of immunogenic cell death may offer personalized strategies to optimize anti-tumor immunity. Once again, the spotlight is on NF kappa B, which is not only a master regulator of cancer cell death, survival, and inflammation, but also of adaptive anti-tumor immune responses that are triggered by dying tumor cells.

Automated summary

Cell biology research has made significant contributions in improving anti-cancer therapies by studying different forms of regulated cell death, identifying master regulators such as NF kappa B, and translating these findings. In the era of immunotherapy, the targeted induction of immunogenic cell death is becoming increasingly important for optimizing anti-tumor immunity.